BETTER BUILDINGS FOR BETTER PHARMACEUTICAL PRODUCTION

May 28, 2019

Embracing and investing in new technologies is one way to get ahead, and adopting lean, efficient manufacturing procedures is another. At a fundamental level, achieving efficiency can start at the outset of a project by considering the very design of a production facility. Careful planning can cut costs and reduce waste at all stages, while at the same time ensuring the production of quality products. For both new entrants wishing to establish a position in the sector, and for established OSD producers seeking to successfully expand their product ranges, getting the end product consistently right is, of course, crucial. In this article, we take a look beyond the processes involved in drug manufacture itself, and instead turn our attention to an often overlooked and underappreciated factor of the manufacturing process: that of materials handling.

Spotlight

Karyopharm Therapeutics Inc.

aryopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed.

OTHER WHITEPAPERS
news image

Pharma 2020: Marketing the future. Which path will you take?

whitePaper | August 8, 2021

If Pharma is to create a new marketing and sales model that is fit for 2020, it will have to begin by analysing its own value chain to identify opportunities for working more closely with healthcare payers and providers. It will, for example, have to collaborate much more closely with payers (be they governments, health insurers, employers or patients) to ensure that it develops medicines which have real social and economic value.

Read More
news image

A BLOCKCHAIN TO ENSURE COUNTERFEIT FREE PHARMACEUTICAL SUPPLY CHAIN

whitePaper | February 5, 2022

Essential medicine access is one of the main objectives of healthcare systems in and pharmaceutical supply chains ensure that the right amount of medicine, with acceptable quality, will reach the customers in need

Read More
news image

Coronavirus (COVID-19) and Its Effect on Pharmaceutical Marketing and Sales

whitePaper | March 16, 2020

With the rapid onset of coronavirus in the United States, many pharma companies are being forced to prepare for a scenario in which their reps cannot visit providers and patients are limited in their ability to visit their healthcare professionals (HCP). The CDC has gone as far as recommending the use of telemedicine and patient portals as primary channels for HCPs and patients to interact.

Read More
news image

2022 Global Life Sciences Outlook

whitePaper | January 3, 2022

While valuations for the life sciences sector in this past year have been mixed, the underlying performance and outlook for the

Read More
news image

Deck 7 Webinars and Virtual Events

whitePaper | January 1, 2020

If you recognize some of these challenges, download the Deck 7 Webinar & Virtual Events overview to see how we make it easy for busy marketers to run highly successful webinars and virtual events....

Read More
news image

BUILDING RESILIENT SUPPLY CHAINS REVITALIZING AMERICAN MANUFACTURING AND FOSTERING BROAD-BASED GROWTH

whitePaper | February 24, 2022

The COVID-19 pandemic and resulting economic dislocation revealed long-standing vulnerabilities in our supply chains. The pandemic’s drastic impacts on demand patterns for a range of medical products including essential medicines wreaked havoc on the U.S. healthcare system.

Read More

Spotlight

Karyopharm Therapeutics Inc.

aryopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed.

Events